Comparative Pharmacology
Head-to-head clinical analysis: CHLORZOXAZONE versus ORPHENADRINE CITRATE ASPIRIN AND CAFFEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORZOXAZONE versus ORPHENADRINE CITRATE ASPIRIN AND CAFFEINE.
CHLORZOXAZONE vs ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Orphenadrine: ~14 hours (range 12-16 h); Aspirin: 2-3 h for low doses, 15-30 h for high/anti-inflammatory doses due to saturable metabolism; Caffeine: 3-6 h in adults, prolonged in liver disease.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Orphenadrine: ~60% renal (metabolites, <8% unchanged), ~20% biliary/fecal; Aspirin: ~80-100% renal (salicylates, dose-dependent; alkaline urine increases excretion); Caffeine: ~1-3% renal (unchanged), main metabolites renal.
Category C
Category A/B
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant